Biotechnology startup Eleusis is exploring sub-perceptual levels of LSD as a potential treatment for Alzheimer’s disease. Company CEO Shlomi Raz explains their short and longer-term strategies.
This post was created with our nice and easy submission form. Create your post!
Enter your account data and we will send you a link to reset your password.
To use social login you have to agree with the storage and handling of your data by this website. Privacy Policy
AcceptHere you'll find all collections you've created before.
Send this to a friend
Comments
Loading…